John J. Fiore

Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced non-small-cell lung cancer treated with combination chemotherapy.

Joseph O’Connell, Mark G. Kris, Richard J. Gralla et al. · Journal of Clinical Oncology · 1986 · 241 citations

Medicine, Oncology, Pharmacology +16

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

M. Catherine Pietanza, Kyuichi Kadota, Kety Huberman et al. · Clinical Cancer Research · 2012 · 187 citations

Medicine, Oncology, Pharmacology +17

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Justin Jee, Emily S. Lebow, Randy Yeh et al. · Nature Medicine · 2022 · 185 citations · Full text

Medicine, Molecular Medicine, Oncology +15

Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes

Jarushka Naidoo, Maria L. Santos-Zabala, Tunç Iyriboz et al. · Clinical Lung Cancer · 2016 · 162 citations · Full text

Medicine, Oncology, Surgery +14

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

Naiyer A. Rizvi, Gregory J. Riely, Christopher G. Azzoli et al. · Journal of Clinical Oncology · 2008 · 121 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17